P78536 (ADA17_HUMAN) Homo sapiens (Human)

Disintegrin and metalloproteinase domain-containing protein 17 UniProtKBInterProSTRINGInteractive Modelling

824 aa; Sequence (Fasta) ; (Isoform 2); 3 identical sequences: Homo sapiens: B2RNB2; Pan troglodytes: A0A2J8NM15; Pan paniscus: A0A2R9BL62

Available Structures

23 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of the TACE-N-TIMP-3 complex Heteromer
P35625;
219-474
ZN;NA;
Assess
Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamidemonomer216-477
ZN;283;
Assess
Crystal structure of TACE in complex with IK682monomer216-475
ZN;541;
Assess
Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' …monomer216-474
ZN;724;
Assess
Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl…monomer216-474
ZN;440;
Assess
Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitormonomer217-475
ZN;IH6;
Assess
Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitormonomer217-475
ZN;4NH;
Assess
Crystal structure of catalytic domain of TACE with carboxylate inhibitormonomer218-475
ZN;INN;
Assess
Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrat…monomer217-474
IPA;INN;ZN;CA;
Assess
Crystal structure of catalytic domain of TACE with hydroxamate inhibitormonomer218-475
ZN;INN;CIT;
Assess
Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitormonomer217-474
Z93;ZN;
Assess
Crystal structure of TACE in complex with JMV 390-1monomer218-475
ZN;INN;
Assess
Crystal structure of TACE in complex with TAPI-2monomer218-474
ZN;CA;INN;IPA;
Assess
Crystal structure of catalytic domain of TACE with tartrate-based inhibitormonomer218-474
ZN;INN;
Assess
Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitormonomer218-474
ZN;INN;IPA;
Assess
Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitormonomer218-474
ZN;727;IPA;
Assess
Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitormonomer218-474
ZN;50X;
Assess
Crystal structure of catalytic domain of TACE with hydroxamate inhibitormonomer218-474
ZN;615;INN;
Assess
Crystal structure of catalytic domain of TACE with hydantoin inhibitormonomer218-474
ZN;INN;IPA;
Assess
Crystal structure of catalytic domain of TACE with inhibitormonomer220-474
ZN;INN;
Assess
CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE)monomer219-473
ZN;INN;
Assess
Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitormonomer221-474
792;ZN;
Assess
The membran-proximal domain of ADAM17monomer581-642
Assess

3 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6bdz.1.Cmonomer0.60223-643
ZN;34.99
Assess
2dw0.2.Amonomer0.53221-644
ZN;27.07
Assess
3k7n.1.Amonomer0.50220-644
ZN;25.29
Assess

3 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26bdz.1.Cmonomer0.60223-643
ZN;34.99
Assess
Isoform 23dsl.1.Amonomer0.52220-644
ZN;27.82
Assess
Isoform 23k7n.1.Amonomer0.51220-644
ZN;25.29
Assess